These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33763790)

  • 21. Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.
    Menna P; Minotti G; Salvatorelli E
    Curr Cardiol Rep; 2019 Mar; 21(5):33. PubMed ID: 30887161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group.
    Lee J; Hur H; Lee JW; Youn HJ; Han K; Kim NW; Jung SY; Kim Z; Kim KS; Lee MH; Han SH; Jung SH; Chung IY
    Cancer; 2020 Jan; 126(1):181-188. PubMed ID: 31454422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study.
    Jacobse JN; Schaapveld M; Boekel NB; Hooning MJ; Jager A; Baaijens MHA; Hauptmann M; Russell NS; Rutgers EJT; Aleman BMP; Sonke GS; van Leeuwen FE
    Breast Cancer Res Treat; 2021 Jan; 185(1):205-214. PubMed ID: 32964358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heart failure after treatment for breast cancer.
    Boekel NB; Duane FK; Jacobse JN; Hauptmann M; Schaapveld M; Sonke GS; Gietema JA; Hooning MJ; Seynaeve CM; Maas AHEM; Darby SC; Aleman BMP; Taylor CW; van Leeuwen FE
    Eur J Heart Fail; 2020 Feb; 22(2):366-374. PubMed ID: 31721395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity.
    Canale ML; Camerini A; Huqi A; Lilli A; Bisceglia I; Parrini I; Lestuzzi C; Del Meglio J; Donati S; Venturini E; Sgambato A; Tarantini L; Amoroso D; Casolo G
    Anticancer Res; 2019 Oct; 39(10):5741-5745. PubMed ID: 31570476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of cancer treatment with excess heart age among five-year young breast cancer survivors.
    Vo JB; Rosenberg S; Zhang BX; Snow C; Kirkner G; Poorvu PD; Gaither R; Ruddy KJ; Tamimi RM; Peppercorn JM; Schapira L; Borges VF; Come SE; Nohria A; Partridge AH
    J Cancer Surviv; 2024 Jul; ():. PubMed ID: 39008138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
    Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
    Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
    Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
    JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decision Science Can Inform Clinical Trade-Offs Regarding Cardiotoxic Cancer Treatments.
    Gillman AS; Vo JB; Nohria A; Ferrer RA
    JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34350379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.
    Meattini I; Curigliano G; Terziani F; Becherini C; Airoldi M; Allegrini G; Amoroso D; Barni S; Bengala C; Guarneri V; Marchetti P; Martella F; Piovano P; Vannini A; Desideri I; Tarquini R; Galanti G; Barletta G; Livi L
    Med Oncol; 2017 May; 34(5):75. PubMed ID: 28364270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.
    Mantarro S; Rossi M; Bonifazi M; D'Amico R; Blandizzi C; La Vecchia C; Negri E; Moja L
    Intern Emerg Med; 2016 Feb; 11(1):123-40. PubMed ID: 26712595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
    Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
    Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
    Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
    Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
    Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of long-term cardiotoxicity and evolution of the systolic function in patients with breast cancer treated with anthracyclines.
    Mata Caballero R; Serrano Antolín JM; Jiménez Hernández RM; Talavera Calle P; Curcio Ruigómez A; Del Castillo Arrojo S; Graupner Abad C; Cristóbal Varela C; Alonso Martín JJ
    Cardiol J; 2022; 29(2):228-234. PubMed ID: 32329038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman.
    Alghafar DA; Younos I; Baimani KA; Al-Salhi D; Al-Riyami A; Rizvi S; Buckley NE
    J Oncol Pharm Pract; 2021 Mar; 27(2):312-321. PubMed ID: 32340535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.
    Martinello R; Becco P; Vici P; Airoldi M; Del Mastro L; Garrone O; Barone C; Pizzuti L; D'Alonzo A; Bellini E; Milani A; Bonzano A; Montemurro F
    Breast J; 2019 May; 25(3):444-449. PubMed ID: 30932296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular Function Phenotypes in Response to Cardiotoxic Breast Cancer Therapy.
    Demissei BG; Finkelman BS; Hubbard RA; Smith AM; Narayan HK; Narayan V; Shah P; Waxman AJ; Domchek SM; Ky B
    J Am Coll Cardiol; 2019 Jan; 73(2):248-249. PubMed ID: 30654897
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.